Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00431340 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase 2 study, sponsored by Valerio Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00431340 is a Phase 2 study that was terminated before completion, run by Valerio Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT00431340, a Phase 2 study, was terminated before completion, sponsored by Valerio Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This open-label study will assess anti-tumor activity and safety of belinostat in combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or relapsed from at least one prior bortezomib-containing regimen. Subjects will be administered both PXD101 and bortezomib on the same days: i.e. days 1, 4, 8, and 11 of a 3-week cycle, for up to 8 cycles.
Interventions
- DRUG PXD101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00431340
The ClinicalTrials.gov registry entry for NCT00431340 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PXD101 is the first listed.
NCT00431340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00431340 about?
NCT00431340 is a clinical study titled "A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma". This open-label study will assess anti-tumor activity and safety of belinostat in combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or relapsed from at least one prior bortezomib-containing regimen. Subjects will be administered both PXD101 and bortezomib on the same ...
What is the current status of trial NCT00431340?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2007-03. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00431340?
The interventions under investigation include: PXD101 (DRUG).
Who is sponsoring clinical trial NCT00431340?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.